The Column Group

Type

Venture Capital

Status

Active

Location

San Francisco, United States

Total investments

120

Average round size

61M

Portfolio companies

44

Rounds per year

6.67

Lead investments

22

Follow on index

0.63

Exits

15

Stages of investment
SeedPrivate EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaEmergency Medicine

Summary

In 2006 was created The Column Group, which is appeared as VC. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the San Francisco.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the The Column Group, startups are often financed by Topspin Partners, OrbiMed, OUP (Osage University Partners). The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Celgene, Versant Ventures. In the next rounds fund is usually obtained by Kleiner Perkins, Foresite Capital, Venrock.

The top amount of exits for fund were in 2019. The important activity for fund was in 2015. Comparing to the other companies, this The Column Group performs on 10 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year.

This organization was formed by Adriana Tajonar, Peter Svennilson. The overall number of key employees were 6.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Health Care, Medical Device. Among the various public portfolio startups of the fund, we may underline Flexus Biosciences, NGM Biopharmaceuticals, Surrozen The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 725000000

Analytics

Total investments
120
Lead investments
22
Exits
15
Rounds per year
6.67
Follow on index
0.63
Investments by industry
  • Biotechnology (115)
  • Health Care (78)
  • Therapeutics (71)
  • Medical (48)
  • Pharmaceutical (39)
  • Show 12 more
Investments by region
  • United States (120)
Peak activity year
2021
Number of Unicorns
4
Number of Decacorns
4
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
136M
Group Appearance index
0.93
Avg. company exit year
6
Avg. multiplicator
2.18
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
InduPro 13 Jun 2024 Early Stage Venture 85M United States, Washington, Seattle
Remix Therapeutics 17 May 2022 Biotechnology, Health Care, Medical, Therapeutics Early Stage Venture 70M United States, Massachusetts, Cambridge

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.